- Conditions
- Pancreatic Cancer
- Interventions
- Tarceva (erlotinib HCl, OSI-774)
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 569 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 60
- States / cities
- Tucson, Arizona • Springdale, Arkansas • Berkeley, California + 51 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 10,867
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C, Chronic, Pregnancy; Infection
- Interventions
- Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
- Drug
- Lead sponsor
- Catherine Anne Chappell
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 6
- States / cities
- Cincinnati, Ohio • Columbus, Ohio • Pittsburgh, Pennsylvania + 3 more
- Conditions
- Smoking Cessation
- Interventions
- NicVAX vaccine, Placebo
- Biological
- Lead sponsor
- Nabi Biopharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Encino, California • Los Alamitos, California + 21 more
- Conditions
- Diabetic Macular Edema
- Interventions
- MYL-1701P, Eylea
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Sacramento, California • St. Petersburg, Florida + 9 more
- Conditions
- Indolent Non-Hodgkin Lymphoma
- Interventions
- Duvelisib
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 24
- States / cities
- Los Angeles, California • Whittier, California • Denver, Colorado + 20 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Intismeran autogene, Pembrolizumab, Placebo
- Biological · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 868 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2035
- U.S. locations
- 68
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Yuma, Arizona + 55 more
- Conditions
- Aortic Valve Stenosis
- Interventions
- CA-TAVR, Amplatzer Duct Occluder
- Procedure · Device
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 15
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • Evanston, Illinois + 12 more
- Conditions
- Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
- Interventions
- CC-122
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 17
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Pain, Bone Neoplasm, Neoplasm Metastasis
- Interventions
- ibandronate [Bondronat], zoledronic acid
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Sedona, Arizona • Ocoee, Florida + 22 more
- Conditions
- Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
- Interventions
- Not listed
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 1 Day to 21 Years
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2031
- U.S. locations
- 13
- States / cities
- Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Interventions
- BMN 110
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- Not listed
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more
- Conditions
- Influenza
- Interventions
- 40 mg Laninamivir Octanoate, 80 mg Laninamivir Octanoate, Placebo
- Drug
- Lead sponsor
- Biota Scientific Management Pty Ltd
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 639 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 70
- States / cities
- Scottsboro, Alabama • Camp Verde, Arizona • Chandler, Arizona + 59 more
- Conditions
- Lung Neoplasms
- Interventions
- CP-547,632
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 20
- States / cities
- Greenbrae, California • San Mateo, California • San Pablo, California + 13 more
- Conditions
- Mesothelin-expressing Advanced Cancers
- Interventions
- ZW171
- Drug
- Lead sponsor
- Zymeworks BC Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 4 more
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor, Breast Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Carcinosarcoma, Ovarian
- Interventions
- PHST001, Paclitaxel, Topotecan, Doxorubicin, FOLFIRI, FOLFOX, Gemcitabine, Mirvetuximab Soravtansine, Trastuzumab Deruxtecan
- Biological · Drug
- Lead sponsor
- Pheast Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Uveitis, Posterior
- Interventions
- Fluocinolone Acetonide Intravitreal Implant 0.18 mg
- Drug
- Lead sponsor
- Alimera Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 23
- States / cities
- Fullerton, California • Glendale, California • Pasadena, California + 20 more
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Interventions
- ASTX727
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 21
- States / cities
- Fountain Valley, California • Plantation, Florida • Chicago, Illinois + 14 more
- Conditions
- Genetics of Drug Metabolism
- Interventions
- Not listed
- Lead sponsor
- General Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • La Jolla, California • Palm Springs, California + 4 more
- Conditions
- Focal Epilepsy
- Interventions
- XEN1101
- Drug
- Lead sponsor
- Xenon Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
- Conditions
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Interventions
- Vutrisiran
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 19 more
- Conditions
- Neoplasms, Ovarian
- Interventions
- MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Sacramento, California • San Francisco, California • Whittier, California + 7 more
- Conditions
- Diabetes Mellitus
- Interventions
- Diabetes Care Gaps Patient Portal Intervention
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- erlotinib, onartuzumab, placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 15
- States / cities
- Bakersfield, California • Fullerton, California • Long Beach, California + 11 more
- Conditions
- Mastectomy, Postoperative Pain, Complications
- Interventions
- Dermamatrix to cover lateral aspect of tissue expander, Serratus anterior to cover lateral aspect of tissue expander
- Procedure
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee